Outset Medical Reports Q1 2026 Financial Results with $27.9M Revenue and Reduced Net Loss

Outset Medical, Inc. reported its financial results for the first quarter of 2026, revealing a total revenue of $27.9 million, a decrease of 6% from $29.8 million in the same period of 2025. The decline was primarily attributed to a 13% drop in product revenue, which fell to $18.6 million from $21.3 million, driven by reduced console and consumable sales. However, service and other revenue increased by 10% to $9.3 million, reflecting growth in the installed base of the company's Tablo Hemodialysis System.

The company's gross profit for the quarter improved to $12.1 million, up from $11.1 million a year earlier, resulting in a gross margin of 43.4%, a significant increase from 37.2% in the prior year. This improvement was largely due to higher average selling prices for consoles and enhanced margins on service revenue, despite lower prices for consumables. Operating expenses rose to $29.0 million, compared to $27.5 million in the previous year, with notable increases in general and administrative costs, which were up 22% due to higher compensation-related expenses.

Outset Medical's net loss for the first quarter was $19.0 million, a reduction from a net loss of $25.8 million in the same quarter of 2025. The company attributed this improvement to a decrease in other expenses, including the absence of a significant loss on extinguishment of a term loan that had impacted the previous year's results. The net loss per share was reported at $1.03, compared to $3.66 in the prior year, reflecting a substantial reduction in the loss per share.

Operationally, Outset Medical continues to focus on expanding its market presence, particularly in the acute care and home dialysis segments. The company has emphasized the importance of its Tablo system, which integrates water purification and on-demand dialysate production, allowing for greater flexibility in dialysis care. As of March 31, 2026, the company had cash, cash equivalents, and short-term investments totaling $160.5 million, providing a solid liquidity position to support ongoing operations and growth initiatives.

Looking ahead, Outset Medical anticipates continued investment in its growth strategies, particularly in enhancing its commercial infrastructure and expanding its customer base. The company expects to incur operating losses in the near term as it aligns its expenses with anticipated revenue growth. Management remains optimistic about the long-term potential of the Tablo system and its ability to drive operational efficiencies and improve patient outcomes in the dialysis market.